1. Complete mtDNA sequencing reveals mutations m.9185T>C and m.13513G>A in three patients with Leigh syndrome
- Author
-
Inna Inashkina, Eriks Jankevics, Irina Adomaitiene, Zita Krumina, Baiba Lace, Evelina Dagyte, Kristina Grigalioniene, Dita Pelnena, Janis Stavusis, Jolanta Rozentale, Liana Pliss, Birute Burnyte, and Algirdas Utkus
- Subjects
Male ,0301 basic medicine ,Mitochondrial DNA ,Nuclear gene ,Mitochondrial disease ,Biology ,medicine.disease_cause ,DNA, Mitochondrial ,03 medical and health sciences ,0302 clinical medicine ,Genetics ,medicine ,Humans ,Leigh disease ,Molecular Biology ,Mutation ,Genetic heterogeneity ,Point mutation ,Infant ,medicine.disease ,030104 developmental biology ,Child, Preschool ,Lactic acidosis ,Female ,Leigh Disease ,030217 neurology & neurosurgery - Abstract
The most common mitochondrial disorder in children is Leigh syndrome, which is a progressive and genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA (mtDNA). In the present study, a novel and robust method of complete mtDNA sequencing, which allows amplification of the whole mitochondrial genome, was tested. Complete mtDNA sequencing was performed in a cohort of patients with suspected mitochondrial mutations. Patients from Latvia and Lithuania (n = 92 and n = 57, respectively) referred by clinical geneticists were included. The de novo point mutations m.9185T>C and m.13513G>A, respectively, were detected in two patients with lactic acidosis and neurodegenerative lesions. In one patient with neurodegenerative lesions, the mutation m.9185T>C was identified. These mutations are associated with Leigh syndrome. The present data suggest that full-length mtDNA sequencing is recommended as a supplement to nuclear gene testing and enzymatic assays to enhance mitochondrial disease diagnostics.
- Published
- 2017
- Full Text
- View/download PDF